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Research Report Summary 
To understand and learn from the diseases they 
encountered, physicians have, from the beginning of 
medicine as a practice, always consciously or 
unconsciously collected data about their patients. The 
information tended to remain with individual physicians, 
and was published or shared, either formally or informally 
with colleagues. As the population has expanded so has 
the drive for knowledge and research. The great 
advances in research and information technology means 
that more statistics, facts, figures and records are being 
collected and shared between groups of physicians and 
researchers than ever before. Underlying the collection of 
data was the tacit understanding, between doctors and 
patients, that all information garnered was confidential; 
given to the doctor in the context of the ethical precepts 
of the doctor-patient relationship. The collection of data in 
its current format by registries has challenged many of 
these age-old practices.  
 
Current issues for discussion include: maintaining 
confidentiality, and exploring the limits of confidentiality. I 
will also look at the issue of informed consent asking if it 
is necessary to obtain informed consent in the context of 
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cancer registries. From an ethical perspective, collection 
and use of information can be viewed from different 
perspectives such as utilitarianism as a social good, and 
respect for persons (often considered as respect for the 
autonomous choices persons make) as an individual 
good. Privacy and the right of an individual to maintain 
control over the type and the degree of information 
shared with others is increasingly becoming a more 
important topic, especially with the advances in the 
communications field and the computerisation of huge 
amounts of data. 
 
In South Africa, the National Cancer Registry is being re-
established. Cancer registration in South Africa has 
become mandatory via statutory regulations. In this 
research report some of the primary ethical and legal 
issues around data collection in South Africa will be 
explored. I will specifically look at issues arising in the 
formation of cancer registries with focus on whether 
registration of cancers infringes on privacy. Privacy in 
South Africa is assured in our Constitution and it is also 
addressed in Common Law. In addition there are other 
South African laws which are relevant; these include the 
National Health Act, the Promotion of Access to 
Information Act, as well as Privacy Laws (which are still 
viii  
being developed). I will explore several of the issues 
concerning the functioning and controls of Cancer 
Registries in some other countries as well as various 
international legal considerations. International 
experiences can serve to inform South African 
healthcare, the public, policies, education and research 
which are all associated with the new South African 
National Cancer Registry. 
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CHAPTER ONE: The South African Cancer 
Registry 
 
1.1. Introduction 
Africa has struggled for decades with the burden of 
infectious diseases such as malaria, tuberculosis, 
diarrhoea and pneumonia. However, the profile of 
diseases in Africa is set to change; the incidence of 
cancer is projected to increase rapidly over the next  
two decades (Valssechi and Steliarova-Foucher, 
2008:159). Cancer in Africa carries a stigma similar to 
that of HIV and it is simply not spoken about by 
patients or their families. Internationally, over 50% of 
cancer cases and approximately 60-80% of the 
deaths from cancer occur in low-income and middle-
income countries (Valssechi and Steliarova-Foucher, 
2008:159; Cavalli, 2008:810) and this figure is 
probably significantly under-estimated. Cancer was 
projected to be the world’s leading cause of death in 
2010 and will kill more people than AIDS, tuberculosis 
and malaria combined (Cavalli, 2008:810).  Cancer 
rates in Africa are set to increase by 400% over the 
next 50 years (Morris, 2003:5).  
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Overall cancer survival rates in Africa are abysmally 
low. Survival rates did not exceed 22% for any cancer 
in the Gambia, and in Uganda survival rates did not 
exceed 13% for any cancer site except breast cancer, 
which was 46% (Sankaranarayanan, et al. 2010: 165). 
Other middle-income and low-income countries like 
China, South Korea, Singapore and Turkey showed 
significantly higher survival rates ranging from 63-82% 
for breast, cervical and bladder cancers, and 44-60% 
survival for large-bowel cancer (ibid:165). Cervical 
cancer is the commonest cause of death in women in 
developing countries, and mortality rates approach 
80% in most regions in sub-saharan Africa (Denny, 
2011: 469). Persistent infection of the cervix with high-
risk Human Papilloma Virus (HPV) has been 
established as being causative in the development of 
cervical cancer. The mortality is higher in Africa than 
in high-income countries, and is mainly due to lack of 
access to diagnostic and anti-cancer therapies (ibid: 
470) as well as a lack of secondary prevention 
measures which include national screening 
programmes and HPV vaccination. 
 
South Africa, despite its affluence, does not have a 
fully-functional or wholly effective national cytology 
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screening programme for the detection of cervical 
cancer. Despite the cervical cytology screening 
programme being slated as a Department of Health 
priority, state oncology departments remain 
overwhelmed with patients presenting with advanced 
cervical cancer, who require intensive treatment 
(Personal Communication Dr Neil Narsai, Consultant 
Oncologist, Dept of Oncology, IALCH). The state 
oncology departments, including radiotherapy 
services, cannot meet the current demands.  
 
The World Cancer Declaration, as noted by Cavialli 
(2008:811) has set out goals for 2020, particularly 
pointing out the requirements for well-planned 
diagnostic and curative services, as well as a 
preventative arm. This is because the financial 
considerations of cancer treatment and prevention are 
extremely costly.  
 
Cancer prevention, diagnosis and treatment are 
enormous problems in low-income and middle-income 
countries where healthcare budgets are often 
constrained in the first instance. At the same time 
without the knowledge of the types and rates of 
cancer, no preventative measures can be enacted. It 
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is therefore necessary that cancer registries be 
established in each country to support this plan to 
provide for the effective management of cancer. 
 
1.2. The World Health Organization (WHO), Union 
for International Cancer Control (UICC) and the 
International Association for Research in Cancer 
(IARC) 
The World Health Organization (WHO) has promoted 
the development of cancer control plans in which the 
role of cancer registries are well defined from as far 
back as the 1950s (Jensen, et al. 1991: 5). The 
International Association for Research in Cancer 
(IARC) was established as the specialised research 
centre of the WHO in 1965 (ibid: 6) The Union for 
International Cancer Control (UICC), which was 
formed in 1933, is the world’s largest international 
non-governmental organisation dedicated to global 
cancer control (UICC, 2010). In 2006, as a call to the 
global cancer world for action to deal with the crisis of 
increasing numbers of patients with cancer (as well as 
the lack of cancer programmes in most countries), the 
UICC put forward an updated World Cancer 
Declaration (Cavalli, 2008:810).  
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According to Cavalli (ibid: 811) the targets of the 
updated World Cancer Declaration are to: ‘make 
available  cancer control plans in all countries; realise 
a substantial improvement in the measurement of 
global cancer burdens; work towards a substantial 
decrease in tobacco consumption, obesity and alcohol 
intake; strive for universal vaccination in areas 
affected by the human papillomavirus (HPV) and 
hepatitis B virus; dispel misconceptions about cancer; 
work towards substantial improvements in early 
cancer detection programmes;  improve globally the 
diagnosis and access to cancer treatment, including 
palliative care, make effective pain control universally 
available; greatly improve training opportunities in 
oncology;  work for a substantial decrease in 
migration of health workers; and to obtain major 
improvement in cancer survival rates in all countries.’ 
 
In order to fulfil these goals, all countries will need to: 
§ Assess the extent of their cancer burden;  
§ Calculate their existing capacity to diagnose 
and treat cancer; and 
§ Monitor the effectiveness of their interventions. 
To be successful, these activities should be co-
ordinated at each country’s national level. In the 
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International Association for Research in Cancer’s 
(IARC) review publication, ‘Cancer Incidence in Five 
Continents (Volume IX)’, there are very few low-
income countries which have collected and submitted 
data. Moreover, concerning the data reported by the 
few reporting low-income countries, there appears to 
be a problem with the quality of the data (Parkin, et al. 
2003).  The quality of cancer registry data is 
evaluated by its “completeness, validity and 
timeliness” (Brooks, et al.  2000: 1131-1140). In 
Africa, there are only five countries that have national 
population-based registers (Morris, 2003:5, Bray, 
2010). South Africa initially had, then lost, and now 
has a National Cancer Registry again.   
 
One of the major problems in low-income countries is 
that cancer registries require funding to be able to 
function effectively. According to Valssechi and 
Steliarovia-Foucher (2008:159), cancer registration in 
low-income countries may be perceived as a luxury 
and therefore has a lower priority in the allocation of 
resources. It follows that without understanding the 
extent of the cancer problem nationally, it is 
impossible to create any type of cancer control, 
treatment and prevention programmes. To bridge this 
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gap, cancer registers should be considered a 
necessity rather than a luxury (ibid). The reasons for 
this are many. Data obtained from a national 
population-based registry will assist in e.g. identifying 
the trends in cancer development which will guide 
further studies in causal relationships. It will assist in 
the assessment of the success or failure of preventive 
interventions and support planning of complete cancer 
care programmes at national levels.  
 
Low and middle-income countries however, are 
fraught with challenges compared to their affluent 
counterparts. Some of these include the fact that 
accurate population statistics are often not available; 
the healthcare infrastructures needed to diagnose and 
treat cancer are poor, health information systems are 
often non-existent; health care priorities are skewed 
towards infectious diseases, and the political will to 
accept and recognise cancer as a significant future 
challenge is simply lacking. 
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1.3. Overview of the history of some national and 
international cancer registries 
Initial efforts at cancer registration started in the 18th 
century. In the 1930’s it was suggested that all cancer 
cases be subject to compulsory notification (Valsecchi 
and Steliarova-Foucher, 2008:160). In the beginning, 
cancer registries were hospital-based, which provided 
some insight into pockets of disease from a clinical 
perspective. However, a national picture, which 
should translate into meaningful government policy on 
cancer, requires a population-based, public-health 
approach to data collection. Some examples of these 
types of national registries follow. 
 
The first well-functioning population based register 
was established in Germany (ibid).  However, the 
German registry was paralysed in mid-1990 as data 
collection drew to a halt because of the increased 
requirements which followed the enacting of privacy 
laws. Two groups submitting data to the German 
Registry in the mid- 1990’s required informed consent 
before information was submitted to the Cancer 
Registry; and as a result, 70% of cases were not 
registered (Duedeck, 2001:9; Bellach and Schon, 
1996:34).  
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In the United States of America (USA), the 
Surveillance Epidemiology and End Result (SEER) 
programme registry is part of the National Cancer 
Institute (NCI). This programme collects and provides 
information on cancer incidence and survival for 28% 
of the USA’s population. Data collection began in 
1973, and continues to expand. The SEER 
programme collects data on patient demographics, 
primary tumour site, tumour morphology and stage at 
diagnosis, first course of treatment and follow-up for 
vital status (SEER, 2010).  
 
The USA’s National Program of Cancer Registries 
(NPCR) under the Centers for Disease Control (CDC, 
2010) was established by the USA Congress though 
the Cancer Registries Amendment Act in 1992 (ibid). 
Prior to the Act, ten US States had no cancer registry, 
and existing registries lacked resources and the 
legislative support needed to collect data. As of 2010, 
the NPCR covers 96% of the USA’s population and, 
together with the SEER programme, the entire 
country is covered. The importance of the SEER 
programme is aptly reflected by R. T. Croyle, Director 
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of the Division of Cancer Control and Population 
Sciences (NCI) as follows: 
‘The SEER program is one of NCI's most 
important data collection and 
dissemination activities. In addition to 
providing essential information for tracking 
the Nation's progress against cancer, 
SEER data and data analysis tools 
provide researchers with unique 
opportunities to explore and explain 
cancer trends. The impact of SEER on 
science, policy, and practice reflects both 
the quality of the data collected and the 
creative expertise of the many scientists 
who use it.’(SEER Brochure, 2008) 
According to the USA’s NPCR, the functions of cancer 
registries are to: “1) Monitor cancer trends over time; 
2) Determine cancer patterns in various populations; 
3) Guide planning and evaluation of cancer control 
programmes; 4) Help set priority for allocating health 
resources; 5) Advance clinical, epidemiologic and 
health services research; and 6) Provide information 
for a national database of cancer incidence. 
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In the United Kingdom (UK), the United Kingdom 
Association of Cancer Registries (UKACR) was 
formed in 1992 in response to rapid changes in both 
information management systems as well as 
demands for accurate data from multiple 
organisations, for the purpose of audit and research 
(UKACR, 2011). Prior to this, cancer registration was 
fragmented and done by several bodies. These 
individual registries realised the need for a formal 
organised cancer registration body to oversee the 
various registries and created the UKACR (ibid).  
 
The Danish Cancer Registry was established in 1942 
and its founder, Johannes Clemmerson, initiated the 
worldwide coordination of cancer registration in 1946 
via the WHO and UICC (Valsecchi and Steliarova-
Foucher, 2008:160).   
 
Worldwide cancer reporting coordination was initially 
located under the auspices of the WHO and UICC, 
and later under the International Association for 
Research in Cancer (IARC). Over 65 years ago, they 
established four principles regarding cancer reporting:  
§ ‘To gather data from as many different 
countries as possible; 
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§ To follow an agreed standard as regards data 
collection; 
§ To have a central record in every country; and 
§ To have an organisation that correlated the 
data from a worldwide perspective’ (ibid: 160). 
 
Currently, the IARC regularly publishes an estimate of 
cancer incidence and mortality worldwide which 
covers 182 national populations and 20 world regions 
(Bray, 2010).  Startling but unsurprising figures on 
cancer registration, according to the IARC, show 
extremes in world cancer registration coverage 
ranging from highs of e.g. 99% in North America and 
Canada, 86% in Australia, to mid-lines e.g. 57% in 
Europe and Russia; to lows of 21% for South 
America, 11% for Africa and 8% for the Middle and 
Far East (ibid). 
 
As shown in these examples, formalised national 
cancer registries have the potential to feed into their 
own country’s science and technology research and 
development programmes. Moreover, if national 
cancer registries contribute to a global system, then 
cancer knowledge and control has the potential to 
benefit all humankind.        
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1.4. South African National Cancer Registry (NCR) 
and other South African cancer registries 
The South African National Cancer Registry (NCR), 
based at the National Health Laboratory Service 
(NHLS), had collected data from pathology 
laboratories in both the state and public sectors from 
1986. This data was based on cases identified via 
pathology laboratories since 1985. The reporting of 
cancer data was done on a voluntary basis (LABRAP, 
2011:1).  
 
However, in 2001, many private laboratories refused 
to submit pathology data citing issues of 
confidentiality, infringement of privacy and the lack of 
informed consent as obstacles (NHLS, 2007 and 
2008).  Moreover, the reporting of cancer confined to 
only a pathologic diagnosis failed to recognise the 
impact of the HIV/AIDS pandemic on clinical practice. 
For example, cancers such as Kaposi’s sarcoma, 
common in HIV/AIDS, are clinically recognisable 
based on patient history and clinical presentation 
(personal experience). If notification is based on 
pathology reports only, such cancers will not be 
included in the registry.  
 
14  
Additionally, those cancers diagnosed on the grounds 
of biochemical and haematological results also were 
absent. Clinically-diagnosed hepatocellular, breast 
and cervical cancers, particularly those identified in 
rural areas without laboratory support, would also not 
be included in only a histopathology-definitive 
reporting system (LABRAP, 2011:1).    
 
Mainly the issues of confidentiality, infringement of 
privacy, lack of informed consent were concerns 
which lead to the demise of South Africa’s cancer 
registry. South Africa has not had an annual cancer 
report published since 2001. This has had an impact 
in many public health related areas such as 
epidemiology and is considered by many healthcare 
professionals to be an unacceptable situation.  
 
During this time other agencies developed or 
maintained particular-interest registries. For example, 
the South African Children’s Cancer Study Group 
(SACCSG) and the Medical Research Council’s 
(MRC) Cancer Epidemiology Research Unit (CERG) 
to which I now turn.     
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The South African Children’s Cancer Study Group 
(SACCSG), a registry based at Tygerberg Hospital, 
collects hospital-based data from all units treating 
paediatric oncology patients in South Africa. The 
SACCGS collects data on a named patient basis, and 
does not require informed consent. Unfortunately, 
access to data from the SACCSG registry has been 
immensely problematic. To date, there has been no 
publications reporting on the data collected, nor has 
the data been made available to participating units 
(personal experience).  
  
As part of the Medical Research Council’s (MRC) 
‘Cancer Case Control Study’ certain cancer data 
began in 1995 (MRC, 2010). Of note, their 
researchers obtain informed consent for all 
information used. One major area of research 
concerns breast and gynaecological cancers in black 
South African women. Another area of their research 
is the CERG PROMEC-Oesophageal Study, which 
collects data on the epidemiology of upper 
gastrointestinal and oral cancers (ibid).  
 
Cancer registration in South Africa should have been 
of a quality that warranted its inclusion in the IARC’s 
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‘5 Continents Cancer Report’, but unfortunately 
collection of data largely collapsed. Recognising a 
problem, the National Department of Health held a 
workshop in 2008 to address the issue of notifiable 
conditions and disease surveillance. At the workshop, 
it was decided that cancer would be placed on the 
new list of notifiable conditions to be added to the 
National Health Act, 61 of 2003. And so it was, in the 
form of a Draft regulation, gazetted in December 
2009.  
 
On April 26, 2011 the new Cancer Registry legislation 
was introduced by the South African Minister of 
Health, Dr. Aaron Motsoaledi. The National Cancer 
Registry (NCR) is a specialised division of the 
National Health Laboratory Services (NHLS).1 It is a 
population-based registry which  
 … requires all doctors and [healthcare] 
facilities that confirm cancer cases to report 
their findings to the NCR (LABRAP 2011:1). 
 
                                                        1 Published in notice 380 of Government Gazette 34248 dated 26 April 2011, the regulations state that the NCR will be responsible for collecting, validating, recording, managing and analysing all information in South Africa relating to cancer. Any such information will be made available to organs of state and the public for research (NDoH, 2011). 
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Now signed into law, private laboratories have legal 
protection around issues such as confidentiality, 
infringement of privacy, lack of informed consent. Now 
data can be submitted without fear of potential 
breaches that may result in litigation as this concern is 
covered under the new regulations. Moreover, the 
regulations recognise that cancer may be confirmed 
by other than histopathologic diagnosis only e.g. by 
hematologic, biochemical and clinical diagnosis as 
well.  
1.5.  Principles of Cancer Registration 
In order to understand the ethical and legal issues 
involved in cancer registries, one must understand the 
process of cancer registration as well as the type of 
data collected. In this section, I will explain this 
process. 
 
Cancer registration, as defined by Jensen, et al. 
(1991:22) is  
…the process of continuing, systematic 
collection of data on the occurrence and 
characteristics of reportable neoplasm’s with 
the purpose of helping to assess and control 
the impact of malignancies on the 
community.  
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Cancer registries may be defined as  
… organised systems for the collection, 
storage, analysis and interpretation of data 
on persons with cancer (Coleman, Muir, and 
Menegoz, 1992:1143).  
 
Registries are a critical cornerstone to any cancer 
control programme. This is because the data they 
contain affords the planning for cancer control, 
provides for aetiological hypotheses to be identified, 
allows the success of interventions on an individual 
case basis to be assessed and is a vehicle through 
which the impact of public health interventions can be 
measured. Registries may be either hospital-based, 
population-based or defined according to a particular 
speciality, e.g. breast cancer registry, or a paediatric 
oncology registry. Each of these has their roles to play 
in the effective surveillance and management of 
cancer. 
 
Hospital-based registries focus on the clinical 
features, clinical management and treatment 
outcomes in a small and defined population. 
Population-based registries, serve to identify overall 
incidence and trends over time in a defined 
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geographical area. Sources of information vary 
according to the type of registry. For hospital-based 
registries gathering information would entail extracting 
a patient’s details from e.g. the medical records 
department, radiotherapy departments, as well as 
outpatient areas and inpatient wards. Pathology 
based registries would need to collect information 
from both the anatomical pathology and haematology 
laboratories. Beyond these are other sources of 
information including speciality registries, national 
government death registers, private clinics and 
hospitals. 
 
Data is usually collected by either active or passive 
reporting. In active reporting there can be an 
established cancer registration service that goes to 
the source e.g. a clinic or hospital, and identifies 
patients at that level. The SACCSG and the 
PROMEC-Oesophageal Study are both examples of 
active reporting. The South African National Cancer 
Registry (SA NCR) was also a form of active 
reporting, the source being the histology samples 
from pathology laboratories. Patients may also opt to 
report their cancers themselves; this is called ‘passive 
reporting’ and is not well-documented in the literature. 
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Active registration is the recommended method of 
data collection (Chokunonga 2010, IARC Workshop) 
According to the IARC’s Guidelines on Confidentiality 
(2004:12), data required for a cancer registry is 
termed ‘patient-identifiable’ data, as the patient’s  
name, surname, gender, date of birth, place of birth, 
current residence, marital status and occupation are 
collected. The reason for collecting data on a 
identifiable-patient basis is to prevent duplications. 
Patient-identifiable data is also required for informed 
epidemiological assessments. The links of cancer to 
e.g. occupation, geographic area, age and sex are 
required to correctly identify trends in presentation 
and survival, as well as the potential risk factors for 
the development of certain cancers. 
 
Registries can opt to collect basic data as per the 
IARC requirements or, if resources are available, can 
expand the amount of optional data that is collected. 
The IARC Guidelines for Confidentiality for Population 
Based Registries divides data for data collection into 
Basic and Optional data as follows: 
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1. Basic Data: 
1.1 Patient demographics: name, sex, age, date of 
birth, usual residential address, and ethnic group. 
1.2 Basic tumour data: the date of diagnosis, basis of 
diagnosis, tumour topography, morphology, and 
tumour behaviour as well as the source of information. 
2. Optional Data: 
2.1 Optional patient demographics: personal 
identification number, place of birth, marital status, 
nationality, and occupation. 
2.2 Optional tumour related data: the clinical extent of 
disease,stage of disease,site of metastasis,multiple 
primaries,initial treatment type, outcome (based on 
date of last contact, status on last contact, date of 
death) and HIV status (dos Santos Silva, 1999:389). 
 
1.6. Elements of cancer data collection 
It is critical to understand the elements of data 
collection, in order to understand the ethical and legal 
challenges that arise. 
 
Cancer registry data is usually captured by registries 
and de-identified to anonymise the data if it used in 
research. Each region within a country may have its 
own registry that collects data according to agreed 
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datasets. A central co-ordinating body may either hold 
the data centrally or may co-ordinate an annual 
analysis of the data. Registry data is held on either 
central or local servers and encryption of data usually 
meets the highest security levels.  
 
If data were collected on an unnamed basis the 
ethical challenges would have been far less, as would 
have been potential public objection. However un-
named / non-identifiable data is definitely less useful, 
and there is a clear case for collecting data on a 
named patient basis together with other identifiers. 
With non-identifiable data, for example the presence 
of duplicate patients’ reports, multiple biopsies from 
the same patient, and repeat notifications as a ‘new 
case’ when a patient has relapsed will all lessen the 
strength of the data and decrease the integrity of the 
database. It is pointless for a registry to exist, unless 
the data is of high quality. Identifiable data can be 
further analysed and used for cancer epidemiology 
research and preventative policy purposes. The use 
of non-identifiable data, I suggest would result in a 
23  
weak registry that ultimately would undermine the 
functioning and success of any cancer programme.2   
1.7. Concluding Remarks  
Following from the discussion thus far there are three 
issues that may be seen to be in conflict with each 
other. The first is the balance with regard to the 
relationship between the physician and his patient 
versus the public dimensions of a disease like cancer. 
Second are the legal and ethical frameworks which 
govern this relationship – viz. individual doctor-patient 
confidentiality and informed consent against public 
health issues. The third relates to making cancer a 
notifiable condition and how best to create the 
balance between legislation governing privacy and 
that of research for the greater benefit to society.  
 
I will develop further some of these issues in my 
second chapter, identifying some of the ethical issues 
which are vital to consider in the formation of a cancer 
registry.  
 
                                                        2 My suggestion is not unique. See for example SEER 2007; Joishy and Driscol 1989. 
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CHAPTER TWO: Exploring Some Ethical 
Aspects of Cancer Registries in South Africa 
 
2.1. Introduction 
Cancer registration in South Africa has become 
mandatory. As noted, some of the ethical questions 
that concern cancer registries include: whether 
informed consent is required and how confidentiality 
and privacy would be maintained. 
Informed consent, confidentiality, and privacy are all 
issues which fall under the principle of respect for the 
autonomy of persons. The idea that we should 
respect persons derives from the works of Immanuel 
Kant (Kant, [1785] 2005). He considered all humans 
to be of intrinsic value, dignity and worth. Because of 
this, we are required to respect not only our own 
dignity, but also the dignity of others. Kant included 
categorical imperatives in his works. His second 
formulation of the categorical imperative tells us that 
all rational persons possess dignity and so they 
cannot use themselves or any others as mere means 
to an end.  This represents a proscription on using 
others as only a means to an end (ibid: 425). Through 
respecting a person’s autonomy we give that person 
dignity in that we value his or her freely made 
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decisions concerning the course of his or her life. It 
follows then that the ideas of informed consent, 
confidentiality and privacy are related to respect for 
persons. Kant’s theory is called ‘deontologic’ because 
it encompasses the individual duties we have to 
ourselves and to others.   Another part of Kant’s 
theory focuses on the intentions of our actions. He 
believed that what matters most is that we always act 
from what he calls a ‘good will’. This means that our 
inner intentions matter. For example if we tried to do 
something good but it turned out badly, for Kant it 
does not matter because our intentions were good.   
 
This is a different perspective to the theory put 
forward by utilitarians. Utilitarianism is type of 
consequentialism. Consequentialist theories look at 
the type of results of actions to judge its morality or 
immorality; if the results are good for all concerned, 
then the action was right. Over two centuries ago, 
Jeremy Bentham (1789) developed a new moral 
principle.  Differing from Kant, Bentham said that the 
goodness of an action should not be judged by our 
intentions.  Instead, he argued that what we should 
use to judge our actions as right or wrong is the utility 
of its consequences (Bentham, 1976). His theory was 
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later refined by John Stuart Mill.  Utilitarianism’s first 
principle is ‘the right action is the one that provides for 
the greatest amount of utility (usually conceived as 
happiness, good or pleasure) for the greatest number 
of people’ (Mill, 1957).  
 
The differences in these theories, particularly finding a 
balance between respect for an individual’s autonomy 
and the public’s good, are issues I will explore further. 
In the following section, I will contextualise these. First 
I will relay my personal experience in the Kwa-Zulu 
Natal Paediatric Haematology Unit, and then I will 
explore the ethical issues of confidentiality and 
informed consent which arise from it.  
 
2.2. KZN Paediatric Haematology Oncology Unit 
experience 
Reflecting on the two registries that my unit 
(Paediatric Haematology Oncology in KwaZulu-Natal) 
regularly submits data to, together with the new 
cancer registry law that has now been acted upon, 
sparked my interests in both the cancer registry and 
other disease specific registries.  
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Submissions from our unit at Inkosi Albert Luthuli 
Central Hospital (IALCH) to the South African’s 
Children’s Cancer Study Group (SACCSG) cancer 
registry, based at Tygerberg Hospital, are done by an 
administration assistant who works between her home 
and IALCH. There are inadequate facilities at IALCH 
to permit her to do all the required work at the 
hospital. This means that there are hard copies (paper 
copies) of the oncology cancer registry data in her 
possession as well as data stored at her home at any 
given time. The SACCSG’s current data collection 
method is that data forms are faxed, emailed or 
posted to the registry in Tygerberg. An administration 
assistant at Tygerberg then captures the data onto 
their computer. All data collected is on a named 
patient basis and the data capture sheet is modelled 
along the IARC requirements. The registry manager is 
a consultant based at Tygerberg hospital.  
 
The Paediatric Haematology Oncology Unit in 
KwaZulu-Natal unit has previously received minimal 
funding for registry management. More dedicated 
administration support for registry management was 
received for the first time in 2010. The unit has no 
dedicated computer with secure access to store data. 
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Further, data security is a problem, as there is no 
dedicated office space or computer from which to 
work. 
 
Due to the infrastructural challenges, the access code 
to the computer is shared and the computer itself is 
used at a general work station. Furthermore, while it is 
recognised that data should not be leaving the 
hospital premises, especially as it is being handled by 
a non-medically trained person, this happens out of 
necessity. In addition, the Unit’s administration 
assistant has not signed a confidentiality agreement, 
as none has been created by the SACCSG. She has 
verbally agreed that she is bound to maintaining 
confidentiality, but the lack of a signed agreement is 
of concern to her. 
 
To the best of my knowledge there are no documents 
which detail the function of this registry, e.g.  its day-
to-day logistics and management, issues around 
confidentiality and informed consent, data security 
and the use of data collected by the registry. In 
exploring such issues, my concerns are raised about 
the following issues:  
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1) The unavailability of details relating to the security 
of data at Tygerberg; 
2) The type of system being operated e.g. 
GLOBOCAN or an Access / Excel based system; 
3) The absence of a formal confidentiality agreement 
which should be drawn up by the SACCSG registry 
for staff involved in the registry; 
4) The absence of reciprocal feedback mechanisms 
and information sharing between persons contributing 
to the registry and the registry;3 
5) The lack of patient involvement. Patients are not 
aware of the existence of the registry, nor do they 
know what its aims and objectives are or how the 
information is to be used; and 
6) The absence of transparency or accountability 
concerning the registry in its current format. 
These concerns and objections to the current state of 
the registry were tabled at a SACCSG meeting in 
2008 and again in 2009. A request was submitted that 
a committee, with a representative from each 
contributing unit, be constituted to manage the                                                         3  As of this writing, no report has ever been issued from the registry to those who submit data. Requests for figures of Paediatric cancer incidence in South Africa, as well as figures for KwaZulu-Natal have been ignored. Such data was to be used in presentations to the MRC as well as to the Department of Health to motivate for additional staff to expand the current units; as a result, the failure of the registry to supply such information to the contributing units compromises each unit’s ability to improve cancer-related health care. 
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registry. To date there has been no further response 
or action on the concerns raised and suggestions 
submitted. As such, the current functioning of the 
SACCSG Registry is considered to be irregular and 
sub-optimal, and the registry does not follow the 
principles detailed in the IARC guidelines.  
 
The second registry, the Paediatric Haematology 
Oncology, unit submits data to the Haemophilia 
Registry previously based at the Red Cross Children’s 
Hospital. This, like the SACCSG was initiated by a 
consultant with an interest in haemophilia. Data is 
collected on a named patient basis, as is done in the 
National Cancer Registry.  
 
The significant difference is that additional data 
relating to HIV (Human Immunodeficiency Virus), 
Hepatitis A, Hepatitis B, and Hepatitis C is collected 
as these are of particular relevance to patients with 
haemophilia. In addition family trees are included. 
This registry was previously Excel-based. Data is 
stored on a computer in the registry administrator’s 
office at Red Cross Children’s Hospital. Further 
details pertaining to the security around the data as 
well as access to the computer is not available. Data 
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was submitted to them by a clerk employed by the 
South African Haemophilia Foundation (SAHF) by fax 
and email. All data including data of a sensitive nature 
(viral studies) are stored on the only computer in the 
clinic at King Edward Hospital, which is also the 
general work station.  
 
In 2008, the SAHF decided that there should be a 
change made to a web-based registry and each 
centre should input their data directly.  A Registry 
Committee was established and issues pertaining to 
registries in general were explored in great depth. 
These covered all aspects of the Registry, from the 
aims of the registry, day-to-day functioning, to data 
encryption, secure servers, confidentiality 
agreements, registry reports and access to data. 
Considerable attention to both the legal and ethical 
issues and an in-depth analysis of international 
registries was done to inform our process. The 
question of the need for informed consent was 
particularly important as data of a sensitive nature is 
also being collected.  
 
The recommendations of the Registry Committee 
were presented and tabled for discussion at the 
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annual Medical and Scientific Advisory Council 
(MASAC) meeting. The main challenge to the 
Haemophilia Registry has been the lack of personnel 
to input data. The issues of control over the registry 
have been partially addressed yet this remains a 
contentious issue.   
 
The web-based South African Haemophilia Registry 
serves as a model as to how the process should 
occur in contrast to the current SACCSG cancer 
registry. There is clear definition of the aims and 
functions. Confidentiality issues have been addressed 
both in terms of data security as well as personnel 
who are required to sign a confidentiality agreement. 
The Haemophilia Registry has a patient information 
leaflet which explains the registry and provides details 
of people to contact should there be any public or 
patient queries.   As virology results are being 
collected, it was decided that informed consent would 
have to be taken. The registry will also apply for ethics 
approval at contributing centres; this has thus-far 
been granted for the Western Cape and Free State. In 
addition, funds have been made available for a 
dedicated computer and to assist with paying registry 
staff. The SAHF is a patient organisation that is 
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extremely pro-active and they are the key drivers 
behind the registry. This is because they are acutely 
aware that haemophilia is an expensive condition to 
treat and that in order to lobby government effectively, 
they require a well-functioning registry. 
 
The differences between these registries set the 
context to discuss some ethical issues. These include 
confidentiality, informed consent and the use of data 
in research. The direct involvement of haemophilia 
patients in their registry will allow discussion of the 
concepts of respect for individual autonomy versus 
‘the public good’.    
 
2.3. Confidentiality 
In an individual doctor-patient relationship, 
confidentiality is one of its key components. The idea 
of keeping patient confidences is recorded in almost 
all of the Oaths, ethical guidelines and declarations 
concerning medical practice. For example, part of the 
Hippocratic Oath says,  
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 ... What I may see or hear in the course of 
the treatment, or even outside of the 
treatment, which of no account one must 
spread abroad, I will keep to myself ...4 
 
Keeping patient information confidential is also a 
practical consideration in medical practice. This is 
because patients would not trust a doctor who was 
known to tell their intimately confided information to 
other people (Knapp van Bogaert and Ogunbanjo, 
2009: 194).  In an individual doctor-patient encounter, 
the personal nature of the information a patient gives 
to his or her doctor is grounded in trust (Beauchamp 
and Childress, 1994: 420). Patients rely on their 
doctor to ensure that the information they give will not 
be divulged to a third party without their permission. In 
order for a patient to speak freely and frankly, 
confidentiality must be guaranteed (Jones, 2003:348). 
The link to Kant’s idea of respect for persons is 
demonstrated in the idea of keeping patient 
confidences. 
                                                         
4 It is interesting to note Gostin’s (1997:370) comments that while 
some have interpreted the Hippocratic Oath as requiring physicians to 
maintain patient’s secrets, others have observed that there must be 
some information that "ought to be spread abroad".  
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Here it is important to consider that information is 
transmitted directly to an individual doctor during a 
consultation as well as by other ways as well, for 
example through diagnostic laboratory tests and 
radiographs. In common hospital admission practice 
additional personal information is required such as 
one’s financial situation viz. hospital deposit, medical 
insurance, next of kin, name of current medical 
complaint, previous operations, telephone number of 
friend, and so forth. This type of information falls out 
of the healthcare professional-patient relationship. 
Thus, both private and strictly medical information 
now computerised and linked to other networks may 
and occasionally does become part of the public 
domain (Knapp van Bogaert and Ogubanjo 
2009:194).  
 
The focal point of confidentiality in this regard 
concerns an individual’s choice about whether, to 
whom and how their information is transmitted (ibid). 
Privacy is similar in that it concerns one’s person and 
is value-laden. The distinctions between 
confidentiality and privacy however are often unclear.  
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To begin with, confidentiality in cancer registration 
must take into account the sensitive nature of the 
diagnosis.  The desire by some cancer sufferers to 
hide this information from others is variable; some 
patients are happy with disclosure of their condition to 
family, friends, and the community; whilst other 
patients are extremely secretive. There are several 
levels at which confidentiality needs to be considered.  
 
On one level, the patient is an individual who has a 
relationship with a healthcare professional and 
confidentiality is a cornerstone in the doctor-patient 
relationship. On another level, the patient is a member 
of society; because of this it can be argued that he or 
she has a responsibility to other members of society 
and vice versa. In order for society to respond to the 
needs of communities as a whole, and to the 
individuals that constitute that society, it is imperative 
that information be collected from individuals to inform 
the needs of society. On yet another level, the patient, 
in the context of the cancer registry, can also be 
considered a research subject. The type of research 
however is generally epidemiological in nature as 
opposed to clinical research, and confidentiality 
issues in these two contexts differ.  
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 As previously noted, confidentiality includes  a set of 
constraints that apply to health information of a private 
or sensitive nature which a person has chosen to 
reveal to a treating physician or healthcare 
professional but which should not be revealed to 
others (IARC, 2004:11). Confidentiality in the doctor-
patient relationship from a lay perspective means that 
whatever is disclosed by the patient to the doctor and 
vice versa must remain between these two 
individuals, unless the patient agrees to disclosure to 
another person or healthcare professional. This is of 
course an ideal situation and is based on the notion of 
a single doctor being able to address all of his/ her 
patient’s needs.  
 
In most countries confidentiality is addressed in 
legislation or professional codes of conduct. For 
example, in the United Kingdom (UK), medical 
professionals are required by both the UK’s  Medical 
Act 1983 and the National Health System’s (NHS) 
Codes of Practice 2003 to treat personal information 
disclosed during care as confidential (Baird, et al. 
2009:92). The expectation is that the physician will act 
responsibly in controlling the flow of patient-
identifiable information.  
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Confidentiality also enhances the idea of the 
autonomous patient, as the patient is afforded the 
‘control’ concerning what to do (or not to do) with his 
or her personal information.  
 
The reality of today’s medical environment is very 
different to that of Hippocrates in 5th BCE when there 
was a single patient and a single physician attending 
to his or her care. As science has advanced, the 
number of individuals involved in the care of a single 
patient has grown phenomenally. In most units, whilst 
the initial consultation is with a single doctor, there are 
now several teams of doctors that interact with the 
patient. There are some specialities like Radiology, 
and Laboratory Services, where the doctor often has 
no direct interaction with patients.  
 
Patient information which was previously limited to a 
single file is now available and accessed by multiple 
users, many of whom are non-medical staff. The 
ultimate responsibility for maintaining the 
confidentiality of data lies with the primary treating 
physician (IARC, 2004:18). Whether a physician 
submits data to a registry voluntarily or in fulfilment of 
a legal requirement a patient’s right to confidentiality 
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should be actively protected. In keeping with this, a 
physician has the right to expect that the cancer 
registry will also adhere to strict rules of 
confidentiality.  
 
For the purposes of a Cancer Registry, any data 
collected and stored by the registry, which could 
permit the identification of an individual patient is 
considered confidential data (ECRN, 2002: 5). This 
may include single data fields like name or identity 
numbers, or linked data e.g. date of birth combined 
with sex and address.  
 
According to the IARC Guidelines on Confidentiality 
(2004:2), 
  …. confidentiality in the context of health 
and biostatistical research concerns 
avoiding the disclosure of sensitive and 
identifiable information about a patient to a 
third party. 
 
Although there may be an understanding that all staff 
working at healthcare institutions will maintain 
confidentiality, there is usually a distinction made 
between medical and non-medical staff. The duty to 
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keep all patient information confidential is part of the 
ethos of all healthcare professionals. The nature of 
the relationship that non-medical personnel have with 
patients is different, as it is often less direct and less 
intimate. It is often viewed as a client-clerk 
relationship as opposed to a healthcare professional-
patient relationship. It is for this reason that many 
institutions do not assume that non-medical staff will 
automatically maintain or respect confidentiality, and 
require that a confidentiality agreement or code of 
conduct to be signed.  
 
The IARC in an earlier document on confidentiality 
(Coleman, et al. 1992:1148) recommended that the 
registry staff should sign a declaration stating that 
they will not release confidential information to any 
unauthorised person, and that this declaration should 
remain in force even should they terminate their 
employment. As far back as 1990, the IARC had 
addressed confidentiality and devised a formal Code 
of Conduct to be followed by its member registries. 
The IARC maintains   
 
… that adequate safeguards for the 
patient’s right to privacy can be obtained by 
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adherence to an appropriate code of 
conduct in the operation of the cancer 
registry (Coleman, et al. 1992:1143).  
 
These guidelines were revised in 2002, following the 
European Union’s (EU) directive on the protection of 
individuals with regard to processing personal data. 
Both the International (IARC) and the European 
Cancer Registries Network’s (ECRN) Guidelines on 
Confidentiality deal in detail with the cancer registry 
requirements for confidentiality. Such requirements 
include storage and transmission of data, access to 
data, responsibilities of the registry manager, an oath 
of secrecy or confidentiality document for all staff, 
physical access to the registry, access to computers 
and servers, and the need for encryption and de-
identification of data. Analysis and access to data by 
researchers, health care planners and individuals are 
also included. 
 
Relating these issues to the idea of medical 
confidentiality, it is clear that providing information to a 
national cancer registry, at least when viewed as part 
of the individual doctor-patient relationship, might 
have some difficulties. That is why the idea of 
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utilitarianism, which looks at the good of society, is 
probably a better argument to use. Seen as a public 
good, in that the information gathered has the 
potential to lead to knowledge concerning, e.g. 
possible causative agents leading to cancer 
development, areas of cancer prevalence, 
environmental factors which may contribute to cancer, 
and racial predispositions towards certain cancer 
types provide an argument for submission of 
information which may be considered as confidential. 
In addition, the recognition of confidentiality as an 
important ethos in all doctor-patient relationships is 
supported in ensuring that patient-identifiers will be 
anonymised after factual input. 
 
Concerning the idea that individuals working with 
sensitive information should be involved in keeping 
patient confidence, registry guidelines make clear that 
a formalisation of a confidentiality agreement should 
occur. Moreover, the type of information technology 
systems, their encryption and access should be of 
great concern. As noted in previously in my two 
registry examples, the facts that e.g. 1) there is no 
dedicated computer in a private area set aside for 
patient input, 2) individuals of good will, willing to take 
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on the responsibility of patient input, are often without 
formal support, 3) computers used for data input are, 
by necessity, removed from a ‘secure’ setting to at-
home use because of lack of support, 4) the unknown 
recipient’s data capture system, 5) the lack of feed-
back from registry officials; 4) codes or agreements of 
confidentiality although desired which are not 
formalised and 5) the non-involvement of patients are 
just some elements which may contribute to 
unintentional breaches of patient-data confidentiality.  
            
As a remedy to this, The Institute for Clinical 
Evaluative Sciences (ICES) has listed a number of 
safeguards to ensure confidentiality of personal health 
data. These are, as listed in Gershon and Tu (2008: 
873): 
§  ‘De-identification of data or, if de-identification 
cannot occur, the substitution of an encrypted 
unique numeric identifier for personal 
identifiers by a designated data custodian; 
§ Designation of a privacy officer to implement 
and monitor compliance with all security and 
confidentiality policies and practices; 
§ Stringent physical and electronic security of 
data; 
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§ Limitation of physical and electronic access to 
the data; 
§ Cultivation of an atmosphere of respect for 
privacy and confidentiality, inclusion of 
confidentiality and data protection obligations in 
employment contracts, requirements for 
employees to sign confidentiality pledges 
yearly and to receive adequate and on-going 
training; 
§ Implementation of strict policies and 
procedures to handle, access, use, disclose, 
retain and destroy data; 
§ Established penalties for unauthorized 
attempts to access or disclose data, or to re-
identify de-identified data; 
§ Assessment of potential privacy and 
confidentiality risks for every observational 
study; 
§ Limitations on data use to a need-to-use basis; 
§ Controls on disclosure of study results 
including the stipulation that only aggregate 
results are allowed to be reported; and 
§ Regular reviews and audits, transparency to 
the public, firm oversight and approval by 
independent parties.  
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The lessons learnt from personal experience thus far 
have been that there are possible and unintentional 
breaches of confidentiality in some of the registries. 
This is because data has not been collected 
according to the various guidelines on confidentiality. 
The majority of the contributors to the two registries 
work in state hospitals and deal mainly with indigent 
patients. The data collected for the registries has 
been collected with the aim of improving care and 
services for patients. However, the doctors who 
submit data have a  responsibility for ensuring the 
confidentiality of data.The doctors have submitted the 
details in good faith, and the assumption is that the 
registry would be run ethically as regards 
confidentiality and security of data. Indigent patients, it 
has been shown, have less awareness of their rights, 
and the obligation and responsibility of doctors 
regarding confidentiality (Britz and Ackerman, 2006). 
Maintaining confidentiality and protecting patient 
rights underlie ethical medical practice. Data has been 
presented at international conferences, but there has 
never been any feedback to the affected population or 
the greater South African society.5  
                                                        
5 I have had personal experience with this problem. South African 
Children’s Cancer Registry data was presented as the society 
International Oncology conference in Mumbai, 2007 coordinator.There 
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The re-establishment of the National Cancer Registry 
in South Africa (NCR) should set a precedent in 
determining how cancer registries and other disease 
specific registries should be run in South Africa. There 
should be a clear supervisory role built into the NCR, 
which will ensure that all current breaches of 
confidentiality do not continue or occur in the future. 
Individual cancer registries should all apply to local 
ethics committees for approval; this will also help to 
prevent breaches of confidentiality. The NCR should 
draw up a code of conduct to govern functioning of 
other cancer registries that may exist independently or 
for those which feed data from a regional area into the 
National Register. These are some of the ways in 
which confidentiality may be assured. 
 
Now I turn to another ethical issue in cancer registry, 
the idea of informed consent   
 
2.4. Informed consent 
Cancer registries have a host of functions and one of 
these is in the area of research. Research ethics falls 
under the jurisdiction of many national and 
                                                                                                              
has been no feedback in the form of an annual report or press releases 
from the registry coordinator. 
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international directives, rules, and guidelines.  These 
regulations all focus on the overall aim of protecting 
the subject/participant. In research, great emphasis is 
placed on informed consent. Cancer registries collect 
sensitive information on a named-person basis and 
this is analysed by the local and national registries. In 
addition, cancer or epidemiologic researchers may 
apply for access to information from the cancer 
registry so a single source in which the data is 
‘secure’ may not be completely assured. The question 
then is whether informed consent should be obtained 
from the patient to have his or her data entered.  
 
There are many guidelines detailing the requirements 
for informed consent in research.6 The current 
expectation is a patient-rights or autonomy-centred 
approach. In this perspective, patients have the right 
to information, the right to knowledge, the right to 
have their choices treated with respect, the right to 
exercise free choice, as well as the right to control 
their participation in research e.g. to withdraw without 
prejudice. 
 
                                                        6 See for example, The Declaration of Helsinki (2008),  The Belmont Report (1979), The CIOMS Guidelines (2002), and The Medical Research Council’s Research Ethics Guidelines (2002) .  
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There are very few exceptions to the need for 
informed consent and these require that there be 
negligible danger to the individuals concerned. 
Cassell and Young (2002:314) note that whilst the 
Helsinki Declaration is the explicit standard under 
which ethics committees evaluate research, it does 
not provide useful guidance on the issue of consent 
for health systems research. The Helsinki Declaration 
addresses ethical issues concerned with the effect of 
individual level interventions on an individual.  The 
Helsinki Declaration also divides research into two 
groups, therapeutic and non-therapeutic research 
(ibid).   
 
Individuals participating in non-therapeutic research 
are afforded extra protection, as there is no direct 
benefit to the participant, but there may be significant 
risk. The Helsinki Declaration (2008) states: 
… Subjects must be volunteers and informed 
participants in the research project’ and ‘each 
potential subject must be adequately informed of 
the aims, methods, sources of funding, any 
possible conflicts of interest, institutional 
affiliations of the researcher, the anticipated 
benefits and potential risks of the study and the 
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discomfort it may entail. The subject should be 
informed of the right to abstain from participation 
in the study. 
 
There has always been debate around what 
constitutes informed consent. For example, common 
questions are: How much information should be 
given? What form should it take? Is it acceptable for 
there to be differing standards for literate versus 
illiterate populations? Kottow (2004:565) describes 3 
levels of standards of disclosure: 
1. Professional practice standard – technical 
information 
2. Reasonable person standard – what the 
subject would normally need to know in order 
to render an informed consent 
3. Actual/subjective personal standard – the 
subjects avidness for information which could 
become limitless  
 
In research, full disclosure is required about the 
intervention (treatment, limits of participation, etc.)  
together with details of the risks and possible benefits; 
however, in clinical practice the patient generally does 
not receive information that is detailed to this extent. 
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Chalmers calls this the ‘double standard for consent’ 
(Cassell and Young, 2002: 315). He finds the practice 
scandalous as there is evidence that patients treated 
on research protocols do much better than those 
treated routinely.  How can this be debate be applied 
to the cancer registry? Is it at all applicable?  
 
It is quite clear that the process of informed consent 
works well for consent in relation to an individual. 
However this process does not work for health 
systems research. Health systems research looks at 
what is required by the population and how best to 
deliver this. Cancer registries potentially have both 
components.  
 
Cassell and Young (2002) considered the impact of 
the need for informed consent in organisational 
research within the UK’s NHS. They note that 
organisational change in the NHS, which has been 
spurred on by rapid technological progress, is driven 
by the results of medical research. The NHS has 
experienced problems in conducting organisational 
research, with requests for informed consent, and 
resultant delays at the ethics board review level. They 
argue that as an alternative, methods for seeking 
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community consent for organisational research should 
be acted upon (ibid: 313). Cancer registries are in a 
similar situation; and its results will inform the 
organisation of cancer programmes.  
 
The UK has seen low levels of participation within 
registries due to the requirement for explicit consent 
(Baird, et al. 2009:92). This has led to unacceptable 
levels of bias, which then impact negatively on the 
quality of research. This type of situation could be 
viewed as unethical in itself. Kalra, et al (2006:196), 
states that it is a ‘generally held view that explicit 
consent should be obtained to use identifiable 
personal data for medical research, particularly for 
multicentre or secondary research when people who 
are not part of the original clinical team need access 
to the data. They suggest that, to avoid having to seek 
consent again for each study, the alternative is to 
ensure the data is adequately anonymised (ibid).  The 
problem is that there are no consensus guidelines on 
how to anonymise data; and anonymising data 
thoroughly enough runs the risk of losing critical 
information. Using existing guidelines and laws 
concerning informed consent, a practice model should 
be developed to guide the medical community  
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concerning informed consent and systems research. 
Moreover, such a model should be widely publicised 
so that the public understands exactly how, if and 
when it might happen, their data will be processed 
and confidentiality maintained. Medical and non-
medical staff involved in medical data management 
will also require special training, as well as on-going 
reminders of the confidential nature of the information 
they handle. 
 
According to Haynes, Cook and Jones (2007: 302), 
the pursuit of informed consent for cancer registration 
may sometimes be detrimental. There are also 
concerns that the process itself may result in biased 
sample groups, as some patients would be less 
contactable. There is also significant additional costs 
involved in trying to obtain informed consent and it 
could well be argued that these resources are better 
spent elsewhere. In a study by Tu, et al. (2004) it was 
found that obtaining informed consent from patients 
for the registry of the Canadian Stroke Network led to 
important selection biases. Due to the need for 
informed consent, only 50% of the eligible patients 
participated. The cost of trying to obtain informed 
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consent over two years was 0.5 million Canadian 
Dollars (ibid: 1414).  
Because of this is it was recommended that de-
identified data be collected without obtaining patient 
consent, but with the necessary confidentiality 
measures. This approach has been advocated by 
others, who argue that where health care is funded by 
the public, patients have an obligation to allow their 
data to be used, with the aim of benefiting the overall 
health care system. Moreover, Tu et al. (ibid: 1419) 
recommend that informed consent be obtained if the 
registry includes direct patient interviews and the 
collection of biological samples. It is also 
recommended that waivers for informed consent for 
clinical registries should be carefully considered and 
should be judged by an independent research ethics 
board. 
 
The cancer patient’s reality is often one of a struggle 
for life versus death. The diagnosis and treatment is 
of cancer is not just an arduous and difficult physical 
battle, but is also an emotional nightmare. From 
personal experience, information relating to the 
cancer has to be given with sensitivity and timing is 
paramount. Many patients are in shock after the 
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diagnosis is disclosed. Following this, they have to 
grapple with the realities of treatment e.g. 
chemotherapy, dealing with the side-effects of 
treatment, and the disruption of a normal life routine. 
At the same time they are confronting their own 
mortality. Patients can deteriorate rapidly within days 
of their diagnosis. In this situation, is there ever an 
opportune time to discuss the cancer registry? The 
answer, in my experience, is probably no. To a patient 
in crisis, the things that matter most are the issues 
that immediately impact upon them.  
 
Reflecting on my personal view – I have to consider 
the following. I have made several assumptions: 
firstly, that post cancer diagnosis, the patient is awash 
with such personal and complex sets of emotion that 
he/she cannot be considered to be in a state in which 
such a question ought to be asked.  In a related way, 
seeking consent for inclusion in a cancer registry 
enrolment is hardly a major concern at this point and 
probably is of little interest.  The question I have to 
ask of myself is: Am I deciding his priorities? Am I not 
eroding his autonomy by not seeking informed 
consent? Where does one draw the line between 
assuming a paternalistic attitude, and providing full 
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disclosure? How much of cover do I consciously or 
sub-consciously obtain by evoking the doctrine of 
therapeutic privilege? 
   
The research conducted from a cancer registry is not 
of a homogenous nature. Registry analysis is primarily 
epidemiological research, but researchers can 
request access to further data which may have a 
clinical or applied component. It is often argued that 
cancer registration cannot be subject to the informed 
consent process, as this is too costly, time-consuming 
and more importantly is unnecessary, as it bears no 
direct risk to the patient.  
 
However, as we do have a moral duty to ensure 
accountability, perhaps representation from patient 
groups is one way around seeking informed consent 
from every patient. This, together with ethically-
minded data managers could cover the 
epidemiological research arm of the registry. If there 
are additional research projects that use data from the 
registry, but are focussed at a more individual level, 
then ethics committees, together with the patient 
advisory groups should review each application on a 
case-by-case basis and decide if informed consent for 
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further studies should be obtained from the patient or 
if deceased, from the patient’s family.  
 
The problem with this model is that Ethics 
Committees themselves do not act similarly when 
faced with a research protocol. Some committees are 
more conservative and apply regulations more 
stringently. A study by Willison, et al (2008:308) into 
how research committees view the request to access 
medical records for research purposes showed 
varying perceptions across different research ethics 
committees.  In the study, thirty research ethics chairs 
and administrators affiliated to faculties of medicine in 
Canada were interviewed. The case presented to 
them for ethical approval without informed consent 
was that of a retrospective chart review. Included in 
the discussion was the question of who may have 
access to the medical record for data abstraction.  
 
The results showed a large variation across sites in 
the requirements for consent for research involving 
access to medical records.  Forty seven per cent of 
the sites required individual consent for the study to 
proceed as proposed, 38% did not require consent, 
10% stated that their response would depend on how 
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potentially identifying variables were going to be 
managed and 7% suggested notification with an opt-
out process (Ibid).  
 
If there are such discrepancies as to how research 
committees view these requests, then perhaps 
patients’ faith in these committees will be lessened. 
This response may be due to misinterpretation of the 
laws, or could be influenced by personal bias. It is 
likely that similar results could be found in a survey of 
research committees in South Africa as well.  Either 
way, there needs to be clear guidelines on data usage 
and a standard interpretation of the laws governing 
privacy. If required, the legal and medical fraternity 
need to work together, to come to a common 
understanding of ethics and the law regarding 
informed consent involving medical records. To make 
inroads into this complex problem, on-going education 
of research committee members is required.  
 
My initial thoughts on the cancer registry were that it 
had to be unethical to collect information, to be shared 
outside the ambit of the treating physician, without 
obtaining informed consent. On reflection of my 
experiences with patients, I cannot think of an 
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opportune moment at which to ask for consent for 
inclusion of data on the cancer registry. It would be 
easy to avoid considering the issue of whether 
informed consent is necessary, by saying that this is 
legislated. This is the stance many of my colleagues 
are adopting when the issue of consent is raised. 
Social contracts can be legislated, and in that case 
the Department of Health would have to ensure 
custody of patient data as well as its analysis and 
reporting. The reality is that just because something is 
mandated by law, doesn’t necessarily mean that it is 
morally correct. Having considered the following as 
regards data capture for cancer registries:  
§ that it is primarily  epidemiological research; 
§ that there would be no ideal opportunity to 
seek informed consent; 
§ that there would be unnecessary financial 
costs incurred; and  
§ that cancer registries should have active 
patient advisory groups and community 
participation 
I consider  that a reasonable argument can be made 
against seeking informed consent in the case of 
cancer registries. The proviso is that any research 
that goes beyond the epidemiological research would 
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require researchers to return to the patients, via their 
physicians to obtain informed consent.  
 
2.5. Patient’s views on Registries 
Numerous  studies have looked at the opinion of 
patients concerning various registries (Baird, et al., 
2009; Helgesson and Swartling, 2008; Barret, et al., 
2006; Singleton and Wadsworth, 2006; Robling. et al., 
2004; Caulfield, Upshur and Daar, 2003; Willison, et 
al. 2003). We should look at how these could inform 
our practice.  
 
Whilst the general consensus is that patients view 
participation in disease registries positively, there are 
some studies that have reported figures of 10%, 17% 
and 25% of patients who refuse to participate (Barret, 
et al. 2006). They conducted a national survey on the 
British public’s view on the use of identifiable medical 
data by their National Cancer Registry and found that 
the majority of the British public did not consider the 
use of personal and identifiable information for the 
purpose of health service research and surveillance to 
be an invasion of privacy. Eighty per cent would 
support a law making cancer registration statutory 
(ibid).  Moreover, a similar study in West Germany in 
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1983, found comparable figures and findings (ibid). 
They further note that despite the NHS code of 
practice on confidentiality assuming that patients will 
not be happy if their information is used for anything 
beyond direct clinical care, their study found that 
patients had no objection to the release of such data if 
the information was used for public health research 
and surveillance (ibid).   
 
Studies that assessed patient’s needs for informed 
consent for the use of personal data show mixed 
results.  In the study by Willison, et al. (2003:373) 
patients at a general practice were interviewed to find 
out their preferences for consent to use information in 
electronic medical records for research.  The patients 
were willing to allow information from their records to 
be used for research, but most preferred to be asked 
for consent verbally or in writing. 
 
Barrett, et al. (2006:4) identified that 93% of the public 
favour the use of non-consent methods in registry-
type research. Only 2% of patients who received a 
study recruitment letter, which included personal 
contact details, felt that their privacy had been 
breached.  81% of the participants in this study 
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supported statutory cancer registration.  Previous 
studies have suggested that patients are content with 
providing registry data without informed consent and 
delegating decision making for further use to research 
ethics committees (Baird, et al. 2009:95).  
 
Caulfield, Upshur and Daar (2003:4) suggest the use 
of an authorisation model for genetic databanks, 
where individual informed consent is obtained for 
initial collection of data and patients then select the 
level of involvement they wish to have in decision 
making in any future use of their data. Whilst such a 
model does grant patients autonomy, it may be 
challenging to obtain the individual informed consent 
at the outset and may depend on the type of data 
collected. Moreover, depending on the type of 
research conducted, informed consent may not even 
be warranted.  
 
For patients battling a life-threatening disease the 
importance of their data might be seen as unimportant 
as they face greater challenges.  Baird, et al. 
(2009:92) interviewed both patients with multiple 
sclerosis (MS), and their physicians on their views 
concerning consent, access to data, and the holding 
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of personal information in a disease specific register. 
Whilst all were positive regarding the benefits of the 
Multiple Sclerosis Register, and patients expressed 
open and altruistic views on the use of their personal 
information to facilitate service provision and 
research, there was an expectation that there should 
be responsible guardianship and the legitimate use of 
their information. Patients also emphasised the trust 
that they had in their physicians to safeguard their 
interests and to act in an ethical manner. 
 
The MS patients also proposed that there should be a 
guardianship committee, made up of involved 
stakeholders to govern the MS Register. These MS 
patients were also concerned that employers may 
have access to the information on the registry and 
they could be further prejudiced.  
 
In the study by Robling, et al (2004:104) which 
investigated the use of primary care data without 
consent, there was general support for research, but 
concerns were expressed about data collection 
without consent. This included a lack of respect for 
patients, a lack in the patients’ control over the 
processes, as well as fears of unauthorised access to 
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the data by others. Interestingly, the same fears were 
verbalised, even with collecting data for population-
based disease registers. Of note, the anxiety 
increased with more sensitive conditions, e.g. mental 
health problems, and the same could be extrapolated 
to cancer. Patients felt that they should be informed 
about data collection as a common courtesy, as well 
as having the option to opt-out. Again, the same 
themes as in the Baird study with regard to security of 
data were echoed.  
 
Another study by Helgesson and Swartling 
(2008:208), considered parental views on data use, 
confidentiality and consent in predictive screening 
involving children.  Respondents cited altruism and 
the desire to assist others in a similar situation as well 
as to contribute to research as motivating factors to 
allow their data to be used. However, of note, the 
participants did not want data to be used beyond the 
reasons for which consent was originally taken. 
 
There are several models proposed for obtaining 
consent to use personal medical data in research. 
These include the Opt-in, Opt-out, Social Contract 
and Anonymous processes (Singleton and 
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Wadsworth, 2006:256). In an Opt-in process each 
potential participant is individually informed about the 
study and their consent is sought and possibly 
formalised in writing. An Opt-out process involves 
individually informing each potential participant about 
the study and they are included unless they object. A 
Social Contract process involves people being 
informed generally about the research. In this process 
information is freely available on specific projects and 
people are included unless they specifically object. 
Finally there is the Anonymous process. In this 
method a system is developed which relies on a 
viable way to anonymise data so that consent is not 
legally required. 
 
Each option has a different cost implication. The cost 
per case in the Opt-in process is constant, but actual 
costs are higher, as patients have to be actively 
recruited. Both the Opt-out and Social Contract 
approach require general information campaigns and 
will incur lower costs, but there will be costs in dealing 
with objections. In cancer registration, the Opt-in and 
Opt-out process both have the possibility of creating 
result bias. In addition they bring unnecessary costs 
into the equation.  
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Patient research into the needs for informed consent 
as discussed in the various studies above has shown 
that generally most patients would not object to data 
collection provided that information about the registry 
was provided, and that necessary steps to maintain 
confidentiality were taken. It would be reasonable to 
use this to justify consent for data usage in cancer 
registries using a combination of the ‘social contract’ 
model together with anonymisation. 
 
2.6. The individual and society: Impact on research 
The Helsinki Declaration is used by all Ethics 
Committees as a fundamental document to guide the 
research process. It’s 5th Amendment (Oct 2000) 
added the following – ‘Medical research involving 
human subjects includes research on identifiable 
human material or identifiable data’. The Declaration 
also states that ethical, legal, or regulatory 
requirements should not be allowed to reduce or 
eliminate any of the protections for human participants 
set forth, and that reports of experimentation not in 
accordance with the principles laid down should not 
be accepted for publication. The requirement for 
informed consent – preferably in writing – is explicit.  
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The reality is that this process is difficult to follow for 
epidemiological research, and may not be necessary, 
provided stringent measures to safeguard information 
are instituted and patient representation, via advisory 
groups, is present on ethics committees. If the current 
requirement for informed consent has to be fulfilled, it 
would cripple any data collection by registries. The 
World Medical Association therefore needs to review 
this Declaration and revise it to address the 
challenges of informed consent in epidemiological and 
organisational research. 
 
According to Helgesson and Eriksson (2008: 54),  The 
Council of Europe’s Convention on Human Rights and 
Biomedicine (1997) states that research that does not 
have the potential to ‘‘produce results of direct benefit 
to the health of the person concerned’’ may be 
authorised if: 
 
‘(a) the dignity, integrity and other rights and 
fundamental freedoms of the research 
participants are respected and protected; 
 (b) they do not object;  and  
 (c) other standard conditions on research 
on human beings are applied, such as that 
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there is no alternative to such research and 
that it entails minimal risk and burden for 
those participating.   
 
While this may serve to show an understanding of the 
need for systems research, Article 3 of the United 
Nations’ (UN) Universal Declaration on Bioethics and 
Human Rights (2005) states,  
 
 ‘the interests and welfare of the individual 
human being shall prevail over the sole 
interest of society or science.’ 
 
 ... which brings us back to the individual versus 
societal benefit debate. Perhaps to mediate this the 
UN’s Universal Declaration on Bioethics and Human 
Rights, Article 14 (UDBHR) (2005) states that the 
promotion of health and social development for their 
people is a central purpose of governments…’ It 
further adds that ...  ‘the enjoyment of the highest 
attainable standard of health is one of the 
fundamental rights of every human being’ and that 
‘progress in science and technology should advance 
access to quality healthcare and essential medicines.’   
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The onus would therefore be placed on government to 
conduct research that would improve healthcare.  
While we see steps towards recognition of the needs 
or good of society, it must be noted that overall it 
remains that the ‘interests of the individual shall 
always prevail over the interest of science and 
society’ (Helgesson and Eriksson, 2008: 54). A 
balance must be found between individual rights and 
those of society, and this should be formally 
recognised in ethical declarations and guidelines. 
Until this is done the tension between the two will 
remain unresolved. Community involvement, which is 
essential to represent societal norms, should be via 
involvement on research committees, rather than 
through stand-alone communities with final vetting 
powers.  
 
There is a view, presented by John Harris (2005), 
which maintains that scientific research is a moral 
duty.  Following the ghastly experimentation on 
human subjects by the Nazi’s in World War II, 
research is sometimes seen as the ‘Frankenstein 
science’ (ibid: 242). The reality is that all of society 
benefits in some way, either directly or indirectly, from 
the gains made by medical research. Harris argues 
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that we have a duty of beneficence to others – a 
moral duty to help others in need. This would fit into 
the concept of fairness, in that we all benefit from 
medical research and we are obliged to contribute to 
that body of research (ibid: 244).  
 
The Declaration of Helsinki, 2008 states ‘In medical 
research on human subjects, considerations related to 
the wellbeing of the human subject should take 
precedence over the interests of science and society’. 
One can immediately appreciate the potential conflict 
if this is to be applied to organisational and 
epidemiological research.  
 
Harris’s (2005) argument is that we have a moral 
obligation to help others, to be just and to share, fits 
very well into the views of our South African society, 
which  espouses to share and care and sees itself as 
‘one’.  When applied to epidemiological and 
organisational research, our moral obligation to 
participate in an activity that does not harm self or 
others and that benefits the greater society should be 
a compelling enough reason to set aside narrowly 
constructed arguments adopted from a different type 
of research. 
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2.7. Concluding Remarks 
The concept of respect for persons includes ethical 
issues such as confidentiality and informed consent. 
Views on autonomy and research include ‘the right of 
people whose body is to be interfered with, be it for 
therapeutic and/or research purposes ... to be fully 
informed about the intended procedure, prior to 
expressing their uncoerced, explicit and revocable 
acceptance to participate (Kottow, 2004:565).7  
 
The conflict between individual confidentiality and the 
societal good can be addressed by taking a purely 
utilitarian view on the collection of data.8 According to 
Robling, et al (2004:108) ‘a perspective in which 
actions should be guided by what produces the 
greatest good for the greatest number presupposes a 
basic confidence in the benevolence of one’s 
government’. At the same time, to neglect the idea of 
respect for persons would be an ethical wrong. 
Robling, et al (2004:108) and Doyal (1997:108) both                                                         7 Kottow (2004) is of the view that subjects have had decreased protection over the last few years and that both informed consent and informed decision-making have been replaced by some degree of paternalism. In the effort to achieve more, on both an individual patient basis as well as for the population, we are risking the rise of paternalism in that decisions or assumptions are made regarding what patients want and how they feel. 8 There is also a rights-based view which conflicts with a utilitarian view; this will be addressed in detail in the legal perspective, discussed in Chapter 3.   
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argue for a moral balance between the needs of the 
individual and community which will offset the moral 
wrong that is committed in not gaining consent for use 
of data, against the benefit accrued to the patient and 
the public. In keeping, we might consider the sharing 
of personal confidential information in the spirit of 
‘sharing and caring’. It is very likely that after 
consultation with the community we may find the 
issues around cancer registration i.e. autonomy, and 
confidentiality may be non-issues. However this 
cannot be presumed and further exploratory studies 
would be needed. 
 
The majority of patients in South Africa who seek 
health care are seen in the State sector, and they are 
treated by a small number of the available doctors in 
the country. The majority of the patients have little 
understanding of their rights and an even lesser 
understanding of the ethics that govern the individual 
doctor-patient relationship, much less the idea of data 
systems collection. These patients are cared for by 
teams of doctors and the relationship between the 
patient and his/her doctor is often far from the original 
ideal.  Due to the vast workload, there is very little 
time available during consultation to address issues 
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beyond immediate management. In many healthcare 
settings, social worker and psychology support are 
either sparse or absent.  The patient’s immediate 
concerns are focussed on their day-to-day survival. In 
addition, the financial burden carried by many patients 
is considerable.  
 
The smaller number of patients seen in the private 
sector will generally have a different relationship with 
their physician, as there is usually more time available 
in the consultation and the level of knowledge around 
their condition is generally higher. Any potential 
breaches of confidentiality can result in litigation in 
both the private and public sector. However, the 
private sector is generally more litigious than the 
public sector. It is therefore likely that it is on the basis 
of fear of litigation from breaches of confidentiality, as 
opposed to ethical concerns surrounding 
confidentiality that dictates how some doctors conduct 
themselves. It was this fear of litigation following 
breaches of confidentiality that led the private 
pathology laboratories to withdraw from submitting 
data to the then-SA National Cancer Registry.  
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The assumption that by making cancer registration a 
statutory requirement that the ethical ideal of patient 
confidentiality is taken care  may in fact  be a false 
sense of comfort or   alternately, can leave one with 
some moral discomfort. I have suggested that if the 
IARC guidelines are followed, every aspect regarding 
confidentiality is covered. All those involved in 
healthcare - physicians, patients, healthcare workers, 
politicians and the broader public - need on-going 
education on the issue of confidentiality in the context 
of a national cancer registry.  There is no doubt that 
the cancer registry and other disease registries are 
powerful tools in clinical medicine and public health. 
However, confidentiality remains a duty. 9 
Researchers are reminded that there is a legal and a 
moral impetus to ensure that research is conducted 
with maximum respect for participants-confidentiality 
and informed consent remain fundamental to the 
ethos of research-even if the research is not linked to 
clinical care. Underlying all our actions as doctors is 
the duty that we have to act in the best interests of our 
patients. 
                                                         9 Kalra, et al (2006:196) calls on researchers to strike a careful balance between their pursuit of health improvements for all and their obligation to maintain privacy of individual research participants. 
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Related to informed consent and confidentiality is the 
idea of privacy. Privacy usually concerns two things 1) 
Control over some information about us and 2) some 
control over who can experience us or observe us   
(Britz and Ackerman 2006).  Privacy is not in itself 
considered an intrinsic good in ethics. It is related to 
ethics in that it concerns the causal relationship 
between an individual’s idea of ‘being in control of 
their own lives’ or their autonomy.  ‘In other words, 
unless a person is in the position to appreciate that 
they have the ability to determine their own course of 
action or to make their own choices, they cannot be 
considered as autonomous agents’ (Knapp van 
Bogaert and Ogunbanjo 2009: 195 ).  When aspects 
of an individual’s life or death are open to public 
scrutiny, then they are open to public experience and 
evaluation, this may imply a disvaluing of one’s 
autonomy (Rachels, 1975: 333). The idea of privacy 
first became an issue under the domain of the law. In 
relation to cancer registries, this is the subject of the 
next chapter. 
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CHAPTER THREE:  Cancer Registries: Exploring 
Some Legal Considerations 
 
3.1. Introduction 
In all legislations concerning cancer registries there 
are two particular concepts that are of great 
importance. The first is Privacy, and the second is that 
of Data Security.10  As in South Africa, different 
countries have a variety of legislations which relate to 
cancer registries. In this chapter, I will look at some of 
these different legislations then comment on our 
South African laws. The legal frameworks impacting 
on cancer registration in South Africa include the 
Constitution, the National Health Act, the Promotion of 
Access to Information Act, Common Law, as well as 
Data Privacy legislation which is still being 
developed.11  
  
                                                        10Data security is an enormous area and, because of the word-restriction, I will not discuss it in this research report. There are several guidelines e.g.  the Anderson’s Guidelines (Denley, Smith, 1999:1329) and the Caldicott Guidelines (1997) that are most comprehensive concerning this topic.  11 I will make only some comments concerning the proposed Data Security legislation. 
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3.2. Privacy 
According to the Privacy International Report (PIR) 
(2003), privacy has ‘roots deep in history’, which 
include Biblical references, as well as protection of 
privacy in early Hebrew culture, classical Greece and 
ancient China. These focused on the right to solitude.  
 
Privacy is a basic human right recognised in the UN 
Declaration of Human Rights (1948), the International 
Covenant on Civil and Political Rights (1966) and in 
many other international and regional treaties and 
documents.  
 
For example, Article 12 of the 1948 Universal 
Declaration of Human Rights states: 
‘No-one should be subjected to arbitrary 
interference with his privacy, family, home 
or correspondence, nor to attacks on his 
honour or reputation. Everyone has the right 
to the protection of the law against such 
interferences or attacks’ 
 
According to the SA Law Reform Commission Report 
on Privacy and Data Protection (2009), Privacy is a 
valuable and advanced aspect of personality. In South 
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Africa, Neethling’s Law of Personality as presented in 
the South African Law Reform Commission’s Report 
(2009: 76) proposes a definition of privacy as follows:  
 
Privacy is an individual condition of life 
characterised by exclusion from publicity. 
This condition embraces all those personal 
facts which the person concerned has 
determined himself to be excluded from the 
knowledge of outsiders and in respect of 
which he has the will that they be kept 
private.  
 
Privacy as a concept flows from the right to be left 
alone, which is a part of the idea of respect for 
persons.  Privacy is a natural right which provides the 
foundation for the legal right. It is an important right 
as it is a necessary condition for other rights like 
freedom and security of person.12  
                                                        12 Some different examples of privacy in legislation follow: The 
Council of Europe’s Convention for the Protection of Human Rights 
and Fundamental Freedoms, Article 8, 1950, states:‘(1) Everyone has the right to respect for his private and family life, his home and his correspondence. (2) There shall be no interference by a public authority with the exercise of this right except as in accordance with the law and is necessary in a democratic society in the interests of national security, public safety or the economic well-being of the country, for the prevention of disorder or crime, for the protection of health of morals, or for the protection of the rights and freedoms of others.’ The Preamble to the Australian Privacy 
Charter (1994) states the following:  
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There is also a relationship between privacy, freedom 
and human dignity. The duty to respect a person’s 
privacy is a prima facie duty. It is not an absolute duty 
that does not allow for exceptions. The right to 
privacy is thus confined by social responsibility. 
 
However, privacy is difficult to define and there is no 
single definition that is universally accepted.  As an 
example, the Calcutt Report (1990) from the UK noted 
that ‘nowhere have we found a wholly satisfactory 
statutory definition of privacy’. They settled on the 
following definition in their first report on privacy:  
 
Privacy is ‘the right of the individual to be 
protected against intrusion into his personal 
life or affairs, or those of his family, by direct 
physical means or by publication of 
information’. 
 
Alan Westin in his 1967 work Privacy and Freedom 
(PIR 2003), defined privacy as  
                                                                                                              
“A free and democratic society requires respect for the autonomy of individuals, and limits on the power of both state and private organizations to intrude on that autonomy. Privacy is a key value which underpins human dignity and other key values such as freedom of association and freedom of speech. Privacy is a basic human right and the reasonable expectation of every person”. 
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‘the desire of people to choose freely under 
what circumstance and to what extent they 
will expose themselves, their attitudes and 
their behavior to others.’ 
 
Edward Bloustein as quoted in the PIR (2003) views 
privacy as an interest of human personality. ‘It 
protects the inviolate personality, the individual’s 
independence, dignity and integrity’. Thus we can see 
that there are many different definitions of privacy but 
all derive from the idea of respecting persons. 
 
In law, privacy can be divided into: 
§ Information Privacy: this covers the collection 
and handling of personal information 
§ Bodily Privacy: this is concerned with the 
protection of the physical body against invasive 
procedures 
§ Privacy of communications: this covers security 
and privacy of all forms of communication 
§ Territorial privacy: this deals with setting limits 
on intrusion into various environments – for 
example the domestic environment and work 
place 
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3.3. Privacy Legislation 
Nearly every democratic country in the world explicitly 
recognises a right to privacy in their constitutions.  
The legal right to privacy is also protected in most 
democratic societies under Private Law. Some of the 
legislations that protect privacy are e.g. the USA’s 
Privacy Act, UK’s Data Protection Act, Australia’s 
Privacy Charter containing 18 privacy principles, and 
the Organisation for Economic Co-ordination and 
Development’s (OECD) Guidelines for the Protection 
of Privacy and Transborder Flow of Personal Data.  
 
The move to legislate privacy began as far back as 
1970 in some countries. The rapid development of 
informational technology has created a need for 
further legislation, as the amount of information 
potentially available in the public domain is ever-
increasing. This has led some countries to revise 
existing legislation and introduce new directives.  
 
In 1981 the Council of Europe passed the directive on 
the ‘Protection of Individuals with regard to the 
processing of personal data and on the free 
movement of such data’. The Directive also requires 
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that data being transferred to countries outside the 
European Union be covered by privacy laws. 
Privacy International (PI) wrote a report entitled 
“Privacy and Human Rights, an International Survey 
of Privacy Laws and Practice” (2003). In the report 
they note that the power, capacity, and speed of 
information technology is accelerating rapidly. With it 
the extent of privacy invasion or the potential thereof, 
there is a corresponding increase in the development 
of further information safeguards. The report also 
notes that other trends contribute to privacy invasion. 
These include amongst others 1) globalisation as it 
has removed the geographical limitations to the flow 
of data and 2) convergence because data systems 
are interoperable with multiple systems  
 
Privacy is an old concept, but it is also a concept 
which has seen more and more challenges as 
technology progresses. In many ways the world as we 
know it has become larger and at the same time it has 
become smaller. Safeguards for privacy have to be 
addressed and constantly revisited in order to 
maintain adequate protection for all. 
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3.3.1. Privacy legislation and research 
Privacy legislation is well-intended and this has 
resulted in formal Privacy Acts in most countries. 
However, in many of these Acts, medical research 
has not been specifically addressed. Trevena, et al 
(2006:476) note that well-intended privacy legislation 
may not have been implemented in line with 
community views, especially as regards the use of 
personal information for health research.  The 
challenge is to balance the privacy rights of 
individuals with the requirements of research intended 
for population/public benefit.  
 
For example, Iverson, et al. (2006:168) discuss their 
struggle in obtaining access to registry data for 
epidemiological research in USA Gulf War veterans. 
Concerning this, the USA Data Protection Act was 
applied in a restrictive manner and data controllers 
created significant obstacles to their research. They 
noted that data controllers and such committees often 
assume that information-based research requires the 
same review procedures and strict principles as is 
applied to interventional research (ibid:170). This 
approach does not take into account, the different 
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sorts of risks involved. They argue that although 
informational privacy is important, 
 ‘it is not nearly as fundamental as the right 
not to be assaulted against your will by a 
medical researcher  as may occur in an 
interventional study (ibid). 
 
The question over whether informational privacy is 
less important than bodily integrity can be debated, 
but the point is made that the ‘proportionality principle 
is misapplied if the risks associated with 
epidemiological research are equated with 
interventional research’ (ibid: 168). 
 
Trevena, Irwig and Barratt (2006:473) conducted a 
trial to assess the impact of Australian Privacy Law on 
research. Potential research participants were 
randomised between an opt-in versus an opt-out 
consent process. They found that opt-in recruitment 
methods markedly decreased the proportion of 
patients recruited into the trial compared to an opt-out 
consent method. In addition, opt-in participants were 
more likely to include active preventive health seeking 
participants as well as those who had a higher risk of 
developing disease. Moreover, the opt-in method 
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tended to under-recruit patients from lower 
educational background. They conclude that this type 
of selection bias is unacceptable and renders any 
research, emanating from this type of study design 
useless (ibid).  
 
Sullivan (2008:1) notes that the impact of legislation in 
the USA has resulted in a downturn in cancer 
research macro-productivity. He also notes that the 
need to comply with all the legislative requirements, 
from local and national research requirements, as well 
as federal law, has substantially increased the mean 
cost per article on cancer research published in the 
USA. In his keynote comment in the Lancet Oncology, 
Sullivan writes,   
 
... We have the perverse situation where 
the emphasis in cancer is now on 
translational and clinical research, while 
the regulatory burden on the areas crucial 
to this endeavour – i.e. clinical trials, use 
of human tissues, and use of data – is 
increased exponentially (ibid). 
 
85  
He also notes that there are many directives that have 
added layers of complex and often contradictory 
regulations to cancer research; these have led to a 
decrease in data collection by registries and have 
negatively impacted on secondary, epidemiological 
and population research. 
 
In the UK, Canada and Europe, individual research 
ethics boards have interpreted these regulations 
differently and this has created further confusion and 
frustration for researchers (Sullivan 2008:2). Current 
cancer research requires international collaboration 
and multicentre studies. Every country has its own 
privacy legislation and every centre has its own 
individual ethics committee, from which approval for 
research must be obtained. This means that there are 
numerous regulations that the same multicentre study 
has to fulfil and this creates a definite barrier to 
collaboration. For such reasons it is appropriate to  
suggest that cancer research should be subject to 
proportionate, fit-for-purpose regulations and that 
researchers, regulatory policy-makers and patient 
groups should drive the process for harmonisation 
and de-regulation. 
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In keeping, I will now look at two examples showing 
some problems and responses to different data and 
privacy protection legislation affecting cancer 
registration.13 
 
3.3.2. The UK experience 
The United Kingdom has had vigorous and extensive 
debate regarding the UK Cancer Registry. The 
General Medical Council (GMC) advised doctors to 
seek patients consent for the disclosure of data to 
cancer registries. This has emanated from both the 
ethical requirements of good medical practice and 
also what is required under their Data Protection Act 
and Common Law of Confidentiality. According to the 
GMC’s Chairman Sir Cyril Chantler (2001:8),  
... patients want an open and honest 
relationship with their physicians, and they 
have a right, legally and ethically, to 
expect their data to be treated as private 
and confidential.                                                          13 In the European Union, Data Privacy Laws, under the title of the 
“European Union’s Directive on the Protection of Individuals with regard to the Processing of Personal Data and Free Movement of Such Data”, (termed ‘The Directive’), are stringently applied to all scenarios including those involving medical research. In the USA the “Health Insurance Portability and Accountability Act” (HIPAA) of  2006 provides the legal requirements governing the collection, transmission and access to data. Over thirty countries have enacted data protection statutes.  
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Debate in the UK has extended over whether 
Parliament should make the necessary changes in the 
law, to make cancer a notifiable condition. 
 
Whilst the 1998 UK Data Protection Act strengthened 
the law protecting an individual’s privacy and enforced 
stricter controls on the use of personal data, the 2001 
Health and Social Care Act made provision for the 
disclosure of patient identifiable information in certain 
circumstances, including medical research (Robling et 
al.  2004:104).14 The UK has seen a number of  
pieces of legislation that impact on the cancer registry 
(Haynes et al. 2007:302). These include the Data 
Protection Act of 1998 (which establishes a series of 
data principles which prescribe how data must be 
processed, maintained and transferred), Section 60 of 
the UK Health and Social Care Act of 2001, the UK 
Common Law of Confidentiality and the UK Human 
Rights Act of 1998.  
 
                                                        14 Similar issues have occurred in the USA, where, despite cancer registration being legislated as mandatory, there are conflicts with the “Health Insurance Portability and Accountability Act” (HIPAA) laws, as well as growing concerns as to whether patient consent should be sought. The balance has to be created between the need for confidentiality and informed consent and the requirements for research and public health surveillance.  
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The UK Data Protection Act specifically covers 
medical research and preventive medicine and allows 
for the creation of a disease register with the 
necessary controls in place. However, the UK 
Common Law of Confidentiality states that patient 
identifiable data should not be provided to third 
parties, regardless of their compliance with the Data 
Protection Act.  
 
Section 60 of the UK Health and Social Care Act of 
2001 now provides for the processing of patient 
identifiable data despite the common law of 
confidentiality (ibid:303). Under this Act, regulations 
may be made which permit the processing of patient 
information for medical purposes deemed necessary 
or appropriate to improve patient care or which are 
considered to be the public’s interest.   
 
The UK Common Law of Confidentiality is based on 
case law and hence is open to interpretation. The UK 
Human Rights Act 1998 states that ‘everyone has the 
right to respect for his private and family life, his home 
and his correspondence’ and that ‘the protection of 
personal data, not least medical data, is of 
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fundamental importance to a person’s enjoyment of 
his or her right to respect for private and family life’.  
 
However, this right is not an absolute right. The UK 
Human Rights Act further provides for the possibility 
that the interests of a patient and community, in terms 
of protecting the confidentiality of medical information, 
may be outweighed by other interests like the 
protection of health. 
 
In 2001 British hospitals began to suspend the flow of 
data to cancer registries (Barrett et al. 2006:1069). 
This was followed by an outcry from cancer registries 
and epidemiologists and a call for clarity in reading 
the conflicting Acts.  As Brewster et al (2001:146) so 
aptly states:  
 
The British Public now faces a stark 
choice. On the one hand, total personal 
autonomy, informed consent before any 
data is shared, and the loss of unbiased 
information about the burden of cancer in 
the community and the outcome of cancer 
treatments and cancer screening 
programmes; on the other hand, 
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legislation to guarantee the availability of 
unbiased, population based health 
information and the obvious benefits that 
flow from this to current and future cancer 
patients and to the wider public.   
 
The UK then established the Caldicott Commission 
(1997) to assess and develop guidelines around data 
collection and privacy. The Caldicott Commission’s 
General Principles of Good Practice provide six 
principles by which one should abide by as regards 
data collection. They are:   
§ ’Principle one is that there must be justification 
for the use and transfer of patient identifiable 
data.  
§ Principle two requires that patient identifiable 
data should be used only where it is absolutely 
necessary. 
§ Principle three requires that the absolute 
minimum necessary patient identifiable data 
should be used. 
§ Principle four states that access to patient 
identifiable data should be on a strict need to 
know basis. 
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§ Principle five requires that all those who have 
access to patient identifiable data should be 
aware of their responsibilities and obligations to 
respect patient confidentiality. 
§ Principle six requires that one understands and 
complies with the laws for the use of patient 
identifiable data’ (Haynes et al 2007:305) . 
 
3.3.3. The Canadian experience 
The Canadian government passed the Personal 
Information Protection and Electronic Documents Act 
in 2000. This was designed to specifically address 
important privacy and confidentiality issues in medical 
research (Gershon and Tu, 2008:178). 
 
Similar to the UK experience, the privacy legislation 
has had a negative effect on observational research, 
in the situation where a waiver of informed consent is 
sought. Most privacy legislation specifically addresses 
when waivers may be obtained.  
 
However, as Gershon and Tu (ibid) note, due to a 
conservative interpretation of this legislation, many 
research boards and data custodians have refused to 
grant waivers and that there are an increasing number 
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of trials where this has resulted in decreased 
participation, selection bias, incomplete research, and 
dismantled disease registries.  
 
These two examples have shown that whilst privacy-
related legislations are enacted with good intention, 
they are not necessarily grounded in the type of 
research and related activities involved in cancer 
registries and registration. Because of this, more or 
more-clearly defined parameters are needed. 
 
3.3.4. South African laws, privacy and cancer 
registries  
 
In terms of the South African Constitution,  every 
person has personality rights, such as the right to 
physical integrity, freedom, reputation, dignity and 
privacy. The South African Law Reform Commission’s 
Report  Project 124 of 2009 lists privacy and data 
protective legislation and codes of conduct which are 
present in South Africa.  They are as follows:  
§ Constitution of South Africa Act 108 of 1996 
§ The Promotion of Access to Information Act 2 
of 2000 
§ The Electoral Act 73 of 1998 
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§ Electronic Communications and Transactions 
Act 25 of 2002 
§ Banking Codes of Conduct 
§ Various best practices - Marketing Federation 
of South Africa 
§ Case law on bodily privacy, privacy of 
communication, territorial privacy15 
 
Concerning privacy, the South Africa Constitution (Act 
108 of 1996) Section 14 provides that: 
 ...everyone has the right to privacy, which 
includes the right not to have –  
9 (a) their persons or homes searched;  
   (b) their property searched;  
   (c) their possessions seized; or  
   (d) the privacy of their communications 
infringed 
 
Importantly, privacy is not an absolute right, but may 
be limited in terms of law of general application and 
has to be balanced with other rights in the constitution 
(SA Law Reform Commission Project 124, 2009:81). 
Privacy can be limited in accordance with the 
                                                        15 No case law on information or data privacy is mentioned in the report. 
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limitation clause of the Constitution contained in 
Section 36.  
 
Section 36 allows for the limitation of rights in the 
South Africa Constitution, Act 108 of 1996’s Bill of 
Rights, provided that the limitation is reasonable and 
justifiable in an open and democratic society based on 
human dignity, equality and freedom. The nature of 
the right, importance of the purpose of limitations, 
nature and extent of limitation as well as the relation 
between the limitation and its purpose also need to be 
taken into account. 
 
South Africa currently does not have a general data 
protection law. The South African Law Reform 
Commission is working on a Data Privacy Act. 
According to their 2009 report concerning the 
proposed Data Privacy Act,  
 ... any data privacy legislation will 
therefore have to find a balance between 
the data subjects fundamental right to 
privacy as set out in section 14 of the 
Constitution on the one hand, and on the 
other hand, other persons’ legitimate 
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needs to obtain information about the data 
subject…  
 
In this we can see that a balance must be found 
between the right to privacy and any oppositional 
rights or interests.  According to Mervyn Dendy 
(2009:1), the approach of the Constitutional Court, in 
the context of privacy, is that,  
 
... it is only the inner sanctum of a person, 
such as his family life, sexual preference 
and home environment that is shielded 
from erosions by the conflicting rights of 
the community. ‘Privacy is acknowledged 
in the truly personal realm, but as a 
person moves into communal relations 
and activities such as business and social 
interactions the scope of personal space 
shrinks accordingly. 
 
As with confidentiality, we can see that there is a 
potential conflict between the rights of the individual 
and the good or need of the community. 
Data Protection laws are required to regulate the 
collection, storage, use and transmittal of personal 
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information Preliminary proposals of Law 
Commission, as set out in its Issue Paper, are 
summarised as follows (Michalson 2004): 
1. Privacy and data protection should be 
regulated by legislation 
2. General principles of data protection should be 
developed and incorporated in the legislation 
3. A statutory regulatory agency should be 
established 
4. A flexible approach should be followed in which 
industries will develop their own codes of 
practice in accordance with the principles set 
out in the legislation) which will be overseen by 
the regulatory agency. 
 
The SA Law Commission highlights the following in its 
summary of proposals in their 2009 “Report on 
Privacy and Data Protection”: 
§ Privacy is a valuable aspect of personality. 
§ Data protection forms an element of 
safeguarding a person’s right to privacy. 
§ Data protection provides for the legal protection 
of a person in instances where his or her 
personal information is being collected, stored, 
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used or communicated by another person or 
institution. 
§ The Constitutional right of privacy is not 
absolute, but may be limited in terms of law of 
general application and has to be balanced 
with other rights. 
§ Competing rights would include the 
administration of national social programmes, 
maintaining law and order, and protecting the 
rights, freedoms and interests of others, 
including their commercial interests. 
 
As privacy is enshrined in the South Africa 
Constitution (Act 108 of 1996) there may be 
challenges to any laws or regulations which are seen 
to interfere with these. The decision to make cancer a 
notifiable condition, under statutory regulations, may 
therefore be challenged on the basis of an 
infringement of privacy.  
 
3.3.5. Public health, individual rights and 
constitutionality of cancer registries  
In the USA, McLaughlin et al (2010:1295) recently 
reviewed a challenge to the constitutionality or not of 
cancer registries. This was based upon two aspects: 
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1)  ‘the vagueness of statutory aims to pursue public 
health versus individual privacy interests of cancer 
patients’ and 2) ‘the alleged indignity of one’s 
individual medical information being transmitted to 
government authorities’.  
  
The Cancer registry statutes, in states covered by the 
National Cancer Institute’s SEER programme and the 
US Centers for Disease Control and Prevention‘s 
National Programme of Cancer Registries, all stated 
specific public health benefits and provide limits and 
safeguards on the government’s possession of private 
medical information.  
 
McLaughlin et al (2010:1296) considered the question 
of whether cancer registries are unconstitutional 
around the five conditions described by Childress et 
al. (2002:170), which provide a ‘rough, conceptual 
map to the terrain of public health ethics’. These 
conditions include  
1) public justification that includes transparency and 
public accountability;  
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2) the least infringement on individual autonomy 
through selection of methods and procedures; and  
3) effectiveness, necessity and proportionality in that 
benefit will outweigh infringed interests.  
 
Mclaughlin et al (2010:1299) found that there was 
minimal infringement of privacy together with high 
public value in the establishment of cancer registries. 
The effectiveness was shown by the significance and 
uses of cancer data. The condition of necessity was 
fulfilled as there are no alternatives to population-
based registers to provide complete and accurate 
epidemiologic data. The final condition of 
proportionality is also achieved as the ‘benefits of 
cancer registration outweigh the moral considerations 
associated with infringed rights’. These are important 
considerations to recall when discussing South 
Africa’s new National Cancer Registry.   
 
3.4. Concluding remarks  
South African legislators and the SA Law Reform 
Commission would do well to give consideration to the 
issues around medical data, its protection, as well as 
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its legitimate use and its use in research, to guide and 
inform better health care for all. As I have shown we 
should take cogniscence of what has occurred in 
other countries particularly the clashes between the 
laws governing privacy and medical research, 
especially in the context of epidemiological studies.  
 
Whilst we need to ensure that privacy is not sacrificed 
in the name of science, we need to make certain our 
citizens may also truly benefit from science while 
being accorded the highest individual privacy-
protection possible. We also need to ensure that all 
documents from professional bodies, as well as the 
Law itself, speak the same language and, importantly 
that all role players have a common understanding of 
the regulations.  
 
Despite the opinion of some who believe that society 
must choose between science and privacy, ‘cancer 
registration does not imply choosing the benefits that 
follow from advancement of medicine over and above 
one’s freedom from arbitrary and unnecessary 
intrusions on privacy’ (McLaughlin, et al. 2010:1298). 
With McLaughlin, et al. we can argue that cancer 
registration that has a clearly defined purpose and the 
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required procedural safeguards can coexist with the 
constitutional right to freedom from arbitrary 
interference with one’s privacy.  
 
More importantly, it succeeds in balancing the right to 
privacy as stated in Article 12 of the Universal 
Declaration of Human Rights with various other rights 
that are stated in the International Covenant on 
Economic, Social and Cultural Rights 1994. These 
rights include the right of everyone to the enjoyment 
of the highest attainable standard of physical and 
mental health; the right to benefit from the efforts of 
government in regard to the prevention, treatment and 
control of epidemic, endemic, occupational and other 
diseases and finally the right of everyone to enjoy the 
benefit of scientific progress and its application.  
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CHAPTER FOUR: Recommendations and 
Conclusions 
 
The burden of cancer that Africa faces now and will 
continue to face in years to come is daunting. 
Diagnostic, surveillance and preventive policies for 
cancer will require information that is reliable, 
consistent and comprehensive. This can only be 
achieved through the National Cancer Registry.  
 
I have shown the importance of clear codes of 
conduct based on sound ethical guidelines. The 
IARC, as well as other established cancer reporting 
confidentiality guidelines may serve as reference 
guidelines for the South African confidentiality 
document.  
 
The registry should function as a central database 
and other independent or special-interest registries, 
like the SA Children’s Cancer Study Group, should 
forward all their data to the NCR.  The new registry, 
as indicated, represents an all-inclusive registry as no 
distinction between patients in the private medical 
sector and the public sector is made. Moreover, by 
extending the type of diagnoses to include clinical and 
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laboratory biomedicine the new NCR shows foresight 
in the realisation that cancer may be diagnosed 
through a variety of scientific means.  
 
The draft regulations relating to cancer registration 
propose the establishment of three registries: the 
National Cancer Registry, the National Childhood 
Cancer Registry and the Population Based Registries. 
The regulation details the reporting structure, which is 
primarily the Director General. Concerning the overall 
transferring of information to healthcare professionals 
administrators, and the public, details concerning e.g. 
the functioning of the different types of registries, 
issues of confidentiality, informed consent and 
regulations concerning safe-data transfer should be 
transmitted openly to all.  
 
An analysis of the current functioning of existing 
cancer registries, as well as other disease specific 
registries, will assist in evaluating the current thinking 
and functioning of registries in South Africa. This will 
provide insight into physician’s views on confidentiality 
and informed consent. The public also needs to be 
consulted, possibly via existing cancer support 
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organizations as well as at a broader based 
community level. 16 
 
The issue of confidentiality needs input from ethicists, 
physicians, lawyers and wider consultation with the 
public. As part of the registry process, studies should 
be done in order to assess the public’s view. Several 
studies have been performed in high-income 
countries and the Western world, but if replicated in 
South Africa, this would lead to greater knowledge.  
This is because Africa tends to view these issues in 
the spirit of Ubuntu and the community sees itself as a 
whole. This is different from the Western view where 
the individualised ‘I’ and a rights centred view is more 
dominant. 
 
The Health Professions Council of South Africa 
(HPCSA) should also work on guidelines that provide 
an understanding of the registry-research perspective. 
This should address issues such as confidentiality 
and the need, or not, for informed consent in 
registries, taking into account the various laws that 
impact on this. In addition as part of continuing 
education, healthcare professionals, such as doctors                                                         16  For example The Cancer Association of South Africa (CANSA) and the Childhood Cancer Foundation South Africa (CHOC). 
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and researchers should be engaged in the topic of 
their moral duty to act in the good of their patients. 
One way is by way of sharing information with them 
such as possible concerns about confidentiality, and 
privacy.  Beyond the individual patient, an active and 
on-going national campaign for the purpose of 
educating the public about the National Cancer 
Registry is vital.   
 
It is not feasible to obtain individual informed consent 
for cancer registration for the reasons I have raised in 
this research report.  It is equally perceivable that 
informed consent need not be required if the research 
conducted is of an epidemiological nature. The 
challenge remains concerning how to process and 
respond to requests for data sets where the proposal 
involves research that is more ‘clinical’ in nature.  
 
I suggest that these requests should all be centralized 
and addressed by the National Cancer Registry 
Board. There should be wider inclusion of public 
representation onto Research Ethics Committees and 
the National Registry Board. The current suggestion 
of including one person on the National Cancer 
Advisory Committee should be reconsidered (National 
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Health Act 2003, Govt Gazette 2009). We should be 
cautious and be careful not to allow the final decision 
or total control of the vetting function to lie solely with 
a Patient Advisory Group. Local Ethics committees 
will also need on-going education, to ensure that they 
clearly understand the legal aspects governing 
privacy, and make consistent and reasonable 
decisions. 
 
South Africa should make representations at an 
international level, both to the United Nations and to 
the World Medical Association, to suggest that the 
relevant declarations be revised to take into account 
current challenges and conflicts that are inherent 
therein. 
 
 The National Cancer Registry should look to various 
guidelines to inform their Data Protection Practices, 
including the Caldicott Guidelines, Andersons’ 
Principles of Data. 
 
The South African Constitution recognises the right to 
privacy. However, the Constitutional right of privacy is 
not absolute, but may be limited in terms of law of 
general application and must be balanced with other 
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rights. With the great advances in information 
technology, South African legislators and the SA Law 
Reform Commission would do well to give specific 
consideration to the issues around medical data. 
These include its protection, legitimate use and data 
protection in research.  
 
The establishment of the National Cancer Registry 
and a thorough review of the ethical and legal 
considerations may provide a clear direction for other 
disease specific registries as well. I suggest that there 
should be a greater government impetus to legislate 
this type of data collection, be it either through 
research ethics committees at individual facilities or 
possibly a national coordinating or overseeing registry 
organization. 
 
In this research report, I have attempted to discuss 
some of the complex legal and ethical issues faced in 
setting up the National Cancer Registry in South 
Africa. In Chapter One I have contextualized the 
burden of cancer in Africa and reviewed the current 
state of cancer registration in South Africa. I have 
provided sufficient reason as to why the re-
establishment of the South African Cancer registry is 
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a necessity from a public health perspective. I have 
reviewed the data requirements as per the IARC 
guidelines, as these requirements determine some of 
the ethical and legal issues that require consideration.  
 
In Chapter Two I have noted some of the challenges 
that existing registries face, and explored some of the 
ethical aspects pertaining to cancer registries.  I have 
pointed out that confidentiality is a core component of  
the doctor-patient relationship and it can be protected 
and preserved in the cancer registry if the guidelines 
on confidentiality are held paramount in practice. 
Arguing that there is minimal infringement or harm to 
the patient can obviate the needs for informed 
consent in the cancer registry. I have shown that 
patients generally view registries in an altruistic light, 
and view cancer registration as a benefit to society in 
general.  I have argued that as cancer registries 
provide epidemiologic research for the greater good to 
society, that autonomy can be limited in this context. 
 
In Chapter Three I have explored some of the legal 
considerations that current legislation and case law 
may place on individuals and registries. I have 
focused on the concept of privacy, as it is privacy that 
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is most under threat with any legislation that aims at 
making cancer registration compulsory. Advances in 
medicine and information technology have 
necessitated legislation governing the protection of 
data and privacy. Several countries with established 
national cancer registries have had to review how this 
legislation should deal with the issues of privacy and 
data protection in the research context. Legislation 
has had to be clarified and amended to ensure that 
research, which would provide benefits for the wider 
community, can continue without undermining 
individual rights.  
 
South Africa is still at an early stage in its new 
National Cancer Registry.  I hope that this report will 
help to inform the various bodies that are considering 
how to frame laws and rules that will impact on such 
registries. The issues I explored have clearly justified 
the need for a National Registry for Cancer and that 
the positive benefits provided by such a registry can, 
on balance, be achieved with minimal infringement of 
individual rights and the hope for better healthcare for 
all South Africans. 
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